Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US8846112 | MALLINCKRODT HOSP | Methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation |
Jun, 2029
(5 years from now) | |
US8282966 | MALLINCKRODT HOSP | Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide |
Jun, 2029
(5 years from now) | |
US8293284 | MALLINCKRODT HOSP | Methods of reducing the risk of occurrence of pulmonary edema in term or near-term neonates in need of treatment with inhaled nitric oxide |
Jun, 2029
(5 years from now) | |
US8795741 | MALLINCKRODT HOSP | Methods for treating patients who are candidates for inhaled nitric oxide treatment |
Jun, 2029
(5 years from now) | |
US8431163 | MALLINCKRODT HOSP | Methods of reducing the risk of occurrence of pulmonary edema associated with inhalation of nitric oxide gas |
Jun, 2029
(5 years from now) | |
US8431163 (Pediatric) | MALLINCKRODT HOSP | Methods of reducing the risk of occurrence of pulmonary edema associated with inhalation of nitric oxide gas |
Dec, 2029
(6 years from now) | |
US8282966 (Pediatric) | MALLINCKRODT HOSP | Methods of reducing the risk of occurrence of pulmonary edema in children in need of treatment with inhaled nitric oxide |
Dec, 2029
(6 years from now) | |
US8293284 (Pediatric) | MALLINCKRODT HOSP | Methods of reducing the risk of occurrence of pulmonary edema in term or near-term neonates in need of treatment with inhaled nitric oxide |
Dec, 2029
(6 years from now) | |
US8795741 (Pediatric) | MALLINCKRODT HOSP | Methods for treating patients who are candidates for inhaled nitric oxide treatment |
Dec, 2029
(6 years from now) | |
US8846112 (Pediatric) | MALLINCKRODT HOSP | Methods of distributing a pharmaceutical product comprising nitric oxide gas for inhalation |
Dec, 2029
(6 years from now) | |
US9265911 | MALLINCKRODT HOSP | Gas delivery device and system |
Jan, 2031
(7 years from now) | |
US9408993 | MALLINCKRODT HOSP | Nitric oxide delivery device |
Jan, 2031
(7 years from now) | |
US8776794 | MALLINCKRODT HOSP | Nitric oxide delivery device |
Jan, 2031
(7 years from now) | |
US8776795 | MALLINCKRODT HOSP | Gas delivery device and system |
Jan, 2031
(7 years from now) | |
US8291904 | MALLINCKRODT HOSP | Gas delivery device and system |
Jan, 2031
(7 years from now) | |
US9295802 | MALLINCKRODT HOSP | Gas delivery device and system |
Jan, 2031
(7 years from now) | |
US8573210 | MALLINCKRODT HOSP | Nitric oxide delivery device |
Jan, 2031
(7 years from now) | |
US8573209 | MALLINCKRODT HOSP | Gas delivery device and system |
Jan, 2031
(7 years from now) | |
US8573209 (Pediatric) | MALLINCKRODT HOSP | Gas delivery device and system |
Jul, 2031
(7 years from now) | |
US8573210 (Pediatric) | MALLINCKRODT HOSP | Nitric oxide delivery device |
Jul, 2031
(7 years from now) | |
US9295802 (Pediatric) | MALLINCKRODT HOSP | Gas delivery device and system |
Jul, 2031
(7 years from now) | |
US9408993 (Pediatric) | MALLINCKRODT HOSP | Nitric oxide delivery device |
Jul, 2031
(7 years from now) | |
US9265911 (Pediatric) | MALLINCKRODT HOSP | Gas delivery device and system |
Jul, 2031
(7 years from now) | |
US8291904 (Pediatric) | MALLINCKRODT HOSP | Gas delivery device and system |
Jul, 2031
(7 years from now) | |
US8776795 (Pediatric) | MALLINCKRODT HOSP | Gas delivery device and system |
Jul, 2031
(7 years from now) | |
US8776794 (Pediatric) | MALLINCKRODT HOSP | Nitric oxide delivery device |
Jul, 2031
(7 years from now) | |
US9279794 | MALLINCKRODT HOSP | Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide |
Feb, 2034
(10 years from now) | |
US9279794 (Pediatric) | MALLINCKRODT HOSP | Systems and methods for compensating long term sensitivity drift of electrochemical gas sensors exposed to nitric oxide |
Aug, 2034
(10 years from now) | |
US9770570 | MALLINCKRODT HOSP | Apparatus and method for monitoring nitric oxide delivery |
May, 2036
(12 years from now) | |
US9770570 (Pediatric) | MALLINCKRODT HOSP | Apparatus and method for monitoring nitric oxide delivery |
Nov, 2036
(13 years from now) |
Drugs and Companies using NITRIC OXIDE ingredient
Market Authorisation Date: 23 December, 1999
Treatment: A method of reducing the risk of pulmonary edema in patients in need of treatment with inhaled nitric oxide; A method of providing nitric oxide therapy to a patient by verifying gas information of nit...
Dosage: GAS;INHALATION
Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
---|---|---|---|---|
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US9610265 | MALLINCKRODT HOSP | Reduced dose intravenous acetaminophen |
Nov, 2028
(5 years from now) | |
US10383834 | MALLINCKRODT HOSP | Reduced dose intravenous acetaminophen |
Nov, 2028
(5 years from now) | |
US9987238 | MALLINCKRODT HOSP | Reduced dose intravenous acetaminophen |
Nov, 2028
(5 years from now) | |
US9987238 (Pediatric) | MALLINCKRODT HOSP | Reduced dose intravenous acetaminophen |
May, 2029
(5 years from now) | |
US9610265 (Pediatric) | MALLINCKRODT HOSP | Reduced dose intravenous acetaminophen |
May, 2029
(5 years from now) | |
US9399012 | MALLINCKRODT HOSP | Reduced dose intravenous acetaminophen |
Sep, 2031
(7 years from now) | |
US9399012 (Pediatric) | MALLINCKRODT HOSP | Reduced dose intravenous acetaminophen |
Mar, 2032
(8 years from now) |
Drugs and Companies using ACETAMINOPHEN ingredient
Market Authorisation Date: 02 November, 2010
Treatment: Modified dosing regimen for the management of moderate to severe pain with adjunctive opioid analgesics; Modified dosing regimen for the reduction of fever; Modified dosing regimen for the management ...
Dosage: SOLUTION;INTRAVENOUS
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic